(Q35791752)

10 August 2017

1 reference

title

A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine (English)

1 reference

10 August 2017

1 reference

1

Pierre Van Damme

1 reference

10 August 2017

Koen Van Herck

2

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Expert Review of Vaccines

10 August 2017

published in

1 reference

10 August 2017

volume

3

1 reference

10 August 2017

issue

3

1 reference

10 August 2017

page(s)

249-267

1 reference

Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

21 January 2018

Hepatitis A immunisation

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Decline of hepatitis B carrier rate in vaccinated and unvaccinated subjects: sixteen years after newborn vaccination program in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Combining hepatitis A and B vaccination in children and adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Risk groups for hepatitis A virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Understanding correlates of hepatitis B virus vaccination in men who have sex with men: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Hepatitis vaccines: recent advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Immunogenicity of standard and low dose vaccination using yeast-derived recombinant hepatitis B surface antigen in elderly volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Immunogenicity of Twinrix in older adults: a critical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

A breakthrough case of hepatitis A disease following a full vaccination schedule of three doses of a combined hepatitis A and B vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

A new accelerated vaccination schedule for rapid protection against hepatitis A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Hepatitis A vaccination options for Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

21 January 2018

Vaccination priorities

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Factors Associated With Hepatitis B Vaccination Among Men Having Sexual Relations With Men in Montreal, Quebec, Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Interference of Antibody Production to Hepatitis B Surface Antigen in a Combination Hepatitis A/Hepatitis B Vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.3.3.249

21 January 2018

Identifiers

DOI

10.1586/14760584.3.3.249

1 reference

release_r6w5omnvmjegxee4njwogfoc7i

10 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/r6w5omnvmjegxee4njwogfoc7i

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference